ArticleFrontiers in medicine2026
Spectrum of autoantibodies and other serological parameters in connective tissue disease-associated interstitial lung disease patients.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Connective tissue disease-associated interstitial lung disease (CTD-ILD) is a major cause of morbidity and mortality in autoimmune disorders, yet detailed serological characterization remains limited in Indian cohorts. Objective: This study aimed to evaluate and compare demographic, radiological, autoantibody, and serum profiles between CTD-ILD and non-CTD-ILD patients from Western India and to delineate hospitalization patterns and mortality outcomes among CTD-ILD patients. Methods: This single-centre, cross-sectional study enrolled 200 patients with ILD ( Results: CTD-ILD patients were significantly younger (49 vs. 57 years; Conclusion: CTD-ILD patients demonstrated distinct demographic, radiological, autoantibody, and serological profiles compared to non-CTD-ILD patients, characterized by elevated anti-MDA5, LDH, and pro-inflammatory cytokines alongside lower MMP7 levels, reflecting an immune-driven rather than fibrosis-dominant pathobiology. These findings contribute to bridging the knowledge gap in the serological characterization of CTD-ILD in Indian cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.